Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute.
-
NCI has launched the COVID-19 in Cancer Patients Study (NCCAPS), which will help answer questions about COVID-19’s impact on cancer patients. The study is now open to adults and will later be expanded to include children.
-
On January 1, 2020, the Food and Drug Administration (FDA) began requiring food manufacturers to display updated nutrition facts labels on their product packaging. Experts from FDA and NCI discuss the update and the research that underpins the changes.
-
Women with high-risk breast cancer who engaged in regular exercise before their cancer diagnosis and after treatment were less likely to have their cancer return or to die compared with women who were inactive, a recent study found.
-
For some men with prostate cancer at high risk of spreading, a large clinical trial shows an imaging method called PSMA PET-CT is more likely to detect metastatic tumors than the standard imaging approach used in many countries.
-
The Food and Drug Administration has approved encorafenib (Braftovi) in combination with cetuximab (Erbitux) to treat adults with metastatic colorectal cancer whose tumors have a specific mutation in the BRAF gene, called V600E.
-
NCI scientists, along with experts from other government agencies and academic medical centers, have launched a joint effort to help FDA evaluate commercially available antibody tests for SARS-CoV-2, the coronavirus that causes COVID-19.
-
Researchers are exploring ways to support the psychological and emotional needs of cancer survivors and how to tailor existing approaches to meet the needs of specific individuals or groups.
-
The number of dendritic cells in a tumor may explain why immunotherapies work for some cancers but not others, a new study suggests. In mice, boosting dendritic cells triggered an immune response that slowed pancreatic tumor growth.
-
NCI is developing the capability to produce cellular therapies, like CAR T cells, to be tested in cancer clinical trials at multiple hospital sites. Few laboratories and centers have the capability to make CAR T cells, which has limited the ability to test them more broadly.
-
After rising steadily for decades, the number of people in the United States who die each year from the skin cancer melanoma has dramatically dropped in recent years, results from a new study show. Learn what has contributed to the dramatic decline.